1. Home
  2. |Insights
  3. |Crowell EC/VC Team Represents Marshall Wace LLP in Series B Investment in Elektrofi

Crowell EC/VC Team Represents Marshall Wace LLP in Series B Investment in Elektrofi

Firm News | 1 min read | 06.16.22

San Francisco–June 16, 2022: Crowell & Moring’s Emerging Companies & Venture Capital team advised Marshall Wace, a global alternative asset manager, in its investment in Elektrofi’s Series B venture capital financing transaction. The deal, which closed on May 27, marks the latest in a growing number of successful venture investment representations on behalf of Marshall Wace. With this investment, Marshall Wace continues its healthcare crossover fund strategy, which has focused on innovative developers of new biotechnology, medical device applications, and more.

Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, is developing a formulation system to effectively process a wide range of therapeutic molecules. Its technology has the capacity to process large, increasingly complex, and delicate proteins—including monoclonal antibodies, bispecific, and fusion proteins that will enable researchers to discover and modify more advanced medicines.

The deal was led by Jon O'Connell with contributions from Justin Lurie and Justin Porter.

About Crowell & Moring LLP

Crowell & Moring LLP is an international law firm with offices in the United States, Europe, MENA, and Asia. Drawing on significant government, business, industry and legal experience, the firm helps clients capitalize on opportunities and provides creative solutions to complex litigation and arbitration, regulatory and policy, and corporate and transactional issues.  The firm is consistently recognized for its commitment to pro bono service and its programs and initiatives to advance diversity, equity and inclusion.

Insights

Firm News | 2 min read | 05.22.26

Crowell & Moring Represents Kanders & Company in Acquisition of Ginkgo Bioworks’ Biosecurity Business

May 22, 2026: A Crowell & Moring team represented Kanders & Company in a complex carveout transaction in which Kanders acquired the biosecurity business of publicly traded Ginkgo Bioworks. The resulting company, Perimeter Systems, has launched as the world’s first integrated biosecurity infrastructure platform, designed to transform biological signals into real-time intelligence and accelerate decisive response. At closing, Perimeter secured $60 million in growth capital, led by Kanders in partnership with SCS Financial, Goldcrest Capital, Four Cities Capital, and the Safe Artificial Intelligence Fund (SAIF)....